Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenograftsChristel Larbouret(Inserm), D. Azria(Inserm)Annals of OncologyNovember 4, 200910.1093/annonc/mdp496Cited by 49SaveCiteExport RISWatch citationsRelated Papers<i>In vivo</i> Therapeutic Synergism of Anti–Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas|Clinical Cancer Research|2007|84HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models|Oncotarget|2014|44